Monitoring and Reversal of Anticoagulation and Antiplatelets.
| Autor: | Yost GW; Department of Cardiology, Geisinger Medical Center, 100 North Academy Avenue, Danville, PA 17822, USA. Electronic address: gwyost@geisinger.edu., Steinhubl SR; Department of Cardiology, Geisinger Medical Center, 100 North Academy Avenue, Danville, PA 17822, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Interventional cardiology clinics [Interv Cardiol Clin] 2013 Oct; Vol. 2 (4), pp. 643-663. Date of Electronic Publication: 2013 Jul 09. |
| DOI: | 10.1016/j.iccl.2013.05.008 |
| Abstrakt: | Since percutaneous transluminal coronary angioplasty was first described and the breakthrough studies of the role of stents were reported, the evolution in anticoagulation and antiplatelet therapy used during percutaneous coronary intervention (PCI) has reduced periprocedural ischemic events and stent thrombosis. Although greater combinations and doses of anticoagulation with antiplatelets seem to provide the best protection against thrombogenic and embolic events, there is a significant trade-off with a higher risk of major and minor bleeding episodes. This review article expands on each of the commonly used antiplatelet and anticoagulants used at time of PCI, focusing on drug monitoring and reversal. (Copyright © 2013 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|